A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty Final results of the fluvastatin angiographic restenosis (FLARE) trial

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation. Experimental evidence suggests that fluvastatin may, independent of any lipid lowering action, exert a greater direct inhibitory effect on proliferating vascular myocytes than other statins. The FLARE (Fluvastatin Angioplasty Restenosis) Trial was conceived to evaluate the ability of fluvastatin 40mg twice daily to reduce restenosis after successful coronary balloon angioplasty (PTCA).